Covered recipient · General Payments record
CHRISTEN F KUTZ
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$108,320.18
352 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $70,193.00 | 36 |
| Consulting Fee | $17,246.50 | 14 |
| Travel and Lodging | $11,852.37 | 44 |
| Food and Beverage | $9,011.59 | 257 |
| Education | $16.72 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 6 of 8; records 251–300 of 352 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHRISTEN F KUTZ
NPI 1629138813 · CMS profile ID 10683993
Physician Assistants & Advanced Practice Nursing Providers / Physician Assistant / Medical
COLORADO SPRINGS, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 8; records 251–300 of 352 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629138813?year=2024&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHRISTEN F KUTZ, NPI 1629138813, CMS profile ID 10683993. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 352 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629138813?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). CHRISTEN F KUTZ, NPI 1629138813, CMS profile ID 10683993. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 352 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629138813?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- CHRISTEN F KUTZ, NPI 1629138813, CMS profile ID 10683993, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 8; records 251–300 of 352 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629138813?year=2024&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
352 matching records · $108,320.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 352.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Biogen, Inc. | $2.82 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104845980 | CMS |
| EMD Serono, Inc. | $50.00 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120236516 | CMS |
| EMD Serono, Inc. | $121.00 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120239950 | CMS |
| TG Therapeutics, Inc. | $2,447.50 | 04/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890732 | CMS |
| ABBVIE INC. | $15.56 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1107494594 | CMS |
| PFIZER INC. | $20.39 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130905504 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $32.07 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144510532 | CMS |
| JAZZ PHARMACEUTICALS INC. | $24.85 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151310095 | CMS |
| EMD Serono, Inc. | $148.12 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120239952 | CMS |
| TG Therapeutics, Inc. | $94.49 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890492 | CMS |
| ANI Pharmaceuticals, Inc. | $20.34 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091171466 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.74 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137777617 | CMS |
| PFIZER INC. | $23.92 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130904818 | CMS |
| ABBVIE INC. | $19.18 | 04/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1107494592 | CMS |
| ABBVIE INC. | $27.16 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1107494590 | CMS |
| Biogen, Inc. | $18.35 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104858830 | CMS |
| Celgene Corporation | $7.43 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101078556 | CMS |
| Biogen, Inc. | $218.00 | 04/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104844026 | CMS |
| Biogen, Inc. | $109.00 | 04/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104877172 | CMS |
| EMD Serono, Inc. | $2,910.00 | 04/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120214716 | CMS |
| Biogen, Inc. | $218.00 | 04/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104808681 | CMS |
| Neurelis, Inc. | $21.88 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145666187 | CMS |
| Janssen Scientific Affairs, LLC | $30.04 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078846285 | CMS |
| EMD Serono, Inc. | $30.17 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120239954 | CMS |
| Genentech USA, Inc. | $27.51 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133150520 | CMS |
| PFIZER INC. | $6.08 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130905179 | CMS |
| TG Therapeutics, Inc. | $15.84 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890482 | CMS |
| TG Therapeutics, Inc. | $16.70 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890504 | CMS |
| TG Therapeutics, Inc. | $16.33 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890514 | CMS |
| ABBVIE INC. | $32.91 | 03/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1107494588 | CMS |
| EMD Serono, Inc. | $123.03 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120213158 | CMS |
| EMD Serono, Inc. | $8.18 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120239958 | CMS |
| JAZZ PHARMACEUTICALS INC. | $26.74 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151310097 | CMS |
| Alexion Pharmaceuticals, Inc. | $24.36 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094025810 | CMS |
| Alexion Pharmaceuticals, Inc. | $27.53 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094051396 | CMS |
| ABBVIE INC. | $8.11 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1107494586 | CMS |
| Biogen, Inc. | $5.45 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104873438 | CMS |
| Celgene Corporation | $38.98 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101078550 | CMS |
| EMD Serono, Inc. | $895.17 | 03/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120213702 | CMS |
| EMD Serono, Inc. | $45.00 | 03/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120213712 | CMS |
| TG Therapeutics, Inc. | $11.52 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136890470 | CMS |
| UCB, Inc. | $22.35 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143117745 | CMS |
| ACADIA Pharmaceuticals Inc | $34.22 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148007321 | CMS |
| Teva Pharmaceuticals USA, Inc. | $900.00 | 03/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151503951 | CMS |
| Abbott Laboratories | $25.10 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158620 | CMS |
| EMD Serono, Inc. | $2,134.00 | 03/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120213556 | CMS |
| Amgen Inc. | $4.92 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115840993 | CMS |
| Celgene Corporation | $300.00 | 03/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101078582 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,058.00 | 03/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101207454 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 03/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101207458 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $569,506.58 | 27 |
| PY2024 | Principal investigator | $482,223.27 | 25 |
| PY2023 | Recipient | $19,775.00 | 3 |
| PY2023 | Principal investigator | $296,655.49 | 43 |
| PY2022 | Principal investigator | $140,946.40 | 16 |
| PY2021 | Recipient | $5,814.59 | 2 |
| PY2021 | Principal investigator | $290,542.63 | 24 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | TG Therapeutics, Inc. | $75.00 | 12/23/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200902 |
| Principal investigator 1 | TG Therapeutics, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200900 |
| Principal investigator 1 | TG Therapeutics, Inc. | $50.00 | 12/03/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200898 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,840.00 | 11/30/2025 | Non-covered Recipient Entity Research of the Rockies, LLC | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200405 |
| Principal investigator 1 | TG Therapeutics, Inc. | $43,975.00 | 11/30/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200888 |
| Principal investigator 1 | TG Therapeutics, Inc. | $50.00 | 11/18/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200896 |
| Principal investigator 1 | TG Therapeutics, Inc. | $100.00 | 11/06/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200894 |
| Principal investigator 1 | TG Therapeutics, Inc. | $23,750.00 | 11/01/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200886 |
| Principal investigator 1 | TG Therapeutics, Inc. | $100.00 | 10/23/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200892 |
| Principal investigator 1 | TG Therapeutics, Inc. | $125.00 | 10/07/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200890 |
| Principal investigator 1 | TG Therapeutics, Inc. | $41,550.00 | 10/01/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200882 |
| Principal investigator 1 | TG Therapeutics, Inc. | $34,975.00 | 10/01/2025 | Non-covered Recipient Entity CSNA | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200884 |
| Principal investigator 1 | TG Therapeutics, Inc. | $41,550.00 | 09/30/2025 | Non-covered Recipient Entity Research Center of Southern CaliforniaLLC | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200403 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,242.00 | 09/27/2025 | Non-covered Recipient Entity ROCKY MOUNTAIN RESEARCH AND CONSULTING | Retrospective analysis of Intravenous immunoglobulin (IVIG) infusion switches to immune globulin infusion 10% with recombinant human hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223286005 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,000.00 | 09/26/2025 | Non-covered Recipient Entity Research Of The Rockies | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235994249 |
| Principal investigator 1 | TG Therapeutics, Inc. | $34,975.00 | 08/31/2025 | Non-covered Recipient Entity Research Center of Southern CaliforniaLLC | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200401 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,242.00 | 08/09/2025 | Non-covered Recipient Entity ROCKY MOUNTAIN RESEARCH AND CONSULTING | Retrospective analysis of Intravenous immunoglobulin (IVIG) infusion switches to immune globulin infusion 10% with recombinant human hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223283989 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $93,350.00 | 07/18/2025 | Non-covered Recipient Entity Rocky Mountain Research And Consulting | Retrospective analysis of RW treatment with KarXT in schizophrenia | No dispute reported | 06/30/2026 | 1235994151 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,122.70 | 06/25/2025 | Non-covered Recipient Entity Colorado Springs Neurological Associates, PC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235997920 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,242.00 | 05/15/2025 | Non-covered Recipient Entity ROCKY MOUNTAIN RESEARCH AND CONSULTING | Retrospective analysis of Intravenous immunoglobulin (IVIG) infusion switches to immune globulin infusion 10% with recombinant human hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223279852 |
| Principal investigator 1 | Eli Lilly and Company | $388.00 | 04/01/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | No dispute reported | 06/30/2026 | 1187880119 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $145,100.00 | 02/03/2025 | Non-covered Recipient Entity Rocky Mountain Research And Consulting | Retrospective analysis of the efficacy, safety, and tolerability outcomes after CD20-directed cytolytic antibody treatment switches to ozanimod in patients with relapsing multiple sclerosis (MS) | No dispute reported | 06/30/2026 | 1235994149 |
| Principal investigator 1 | Roche Products Limited | $285.24 | 01/09/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211590064 |
| Principal investigator 1 | Roche Products Limited | $171.16 | 01/09/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211590069 |
| Principal investigator 1 | Roche Products Limited | $285.24 | 01/09/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211590072 |
| Principal investigator 1 | Roche Products Limited | $285.24 | 01/09/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211590077 |
| Principal investigator 1 | Eli Lilly and Company | $17,578.00 | 01/07/2025 | Non-covered Recipient Entity COLORADO SPRINGS NEUROLOGICAL ASSOCIATES | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187878597 |